Abstract
Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Current Signal Transduction Therapy
Title:Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Volume: 7 Issue: 3
Author(s): Eva-Maria Schottdorf
Affiliation:
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Abstract: Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Export Options
About this article
Cite this article as:
Schottdorf Eva-Maria, Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481574
DOI https://dx.doi.org/10.2174/157436212802481574 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
Current Cancer Drug Targets Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets An Overview on 2-arylquinolin-4(1H)-ones and Related Structures as Tubulin Polymerisation Inhibitors
Current Topics in Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry